Plus Therapeutics enters into $17.35M ATM equity distribution agreement with Canaccord Genuity

PLUS THERAPEUTICS, INC.

Up to $17.35M of common stock may be sold at-the-market through Canaccord Genuity as agent.
Commission of 3.0% of gross proceeds plus $75,000 expense reimbursement to Agent.
Proceeds intended for general corporate purposes and working capital.
Sales may be made on Nasdaq Capital Market under Rule 415; no obligation to sell shares.
Offering terminates upon sale of all shares or termination of Distribution Agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PLUS THERAPEUTICS, INC. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at $17,350,000 (effective 2026-06-01).

Action: entry
Agreement: atm program
Counterparty: Canaccord Genuity LLC
Value: $17,350,000
Effective: 2026-06-01

Exact text from the filing

On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent acting as an agent for sales.

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-259703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.